Spondyloarthritis phenotypes: rationale of evaluation in context of personified medicine
https://doi.org/10.33667/2078-5631-2019-2-37(412)-16-21
Abstract
The article contents the analysis of different clinical phenotypes in the most common spondyloarthritis (SpA): ankylosing spondylitis (AS), axial spondylarthritis (axSpA) and psoriatic arthritis (PsA). SpA polymorphism has been discussed on the basis of multiple clinical presentations, structural lesions, radiological, immunological and genetic characteristics. Role of pro-inflammatory agents especially IL-17 in structural progression has been pointed out. Recent data regarding the link between HLA-B27 antigen, gender and age specificity and different clinical manifestation of SpA are presented. Current algorithms for SpA management based on evidence of efficacy sDMARD and/or biologics in separate phenotypes of SpA as well as resistance to DMARD are highlighted. Authors have concluded that meticulous analysis of SpA manifestation and patient’s individual profile is critical in rational SpA management according to personified medicine strategy.
About the Authors
A. R. Babaeva
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
E. V. Kalinina
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
M. S. Zvonorenko
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
I. V. Kostriukova
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
References
1. Гайдукова И. З., Ребров А. П., Лапшина С. А. и др. Применение НПВП и ГИБП для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Ассоциации ревматологов России // Научно-практическая ревматология. 2017; 55 (5): 474–484.
2. Коротаева Т. В. Перспективы применения ингибиторов интерлейкина-17 — нового класса препаратов для таргетной терапии псориатического артрита // Научно-практ. ревматология. 2016; 54 (3): 1–5.
3. В. И. Мазуров, И.З Гайдукова. Современная концепция спондилоартритов. Opinion Leader № 9 (27) 2019. С. 18–29.
4. Насонов Е. Л. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17 // Научно-практ. ревматология. 2017; (1): 68–86.
5. Ревматология. Клинические лекции / Под ред. проф. В. В. Бадокина. М. Литература, 2012–592 с.
6. Российские клинические рекомендации «Ревматология». Под ред. акад. РАН Е. Л. Насонова. ГЭОТАР-Медиа, 2017. 464 с.
7. Смирнов А. В. Рентгенологическая диагностика анкилозирующего спондилита (болезни Бехтерева) — М.: ИМА-ПРЕСС, 2013. 112 с.
8. Asahina A et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase3 study. // J Dermatol 2016; 43: 1311–16.
9. Baraliakos X. et al. Does axial spondyloartritis phenotype correlate with imaging morphotype? // DOI: 10.1136/annrheumdis-2017-eular.3681.
10. Bengtsoon K. et al. How strong are the associations of spondyloarthritis-related co-morbidities with ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis? A registry-based study from Sweden.// DOI: 10.1136/annrheumdis-2017-eular.1255.
11. Clark JD et al. Discovery and development of JAK inhibitors for inflammatory disease J Med Chem 2014; 57: 5023–38.
12. Combe B. et al. 2016 update of EULAR recommendations for the management of early arthritis // Ann Rheum Dis. 2016; 0: 1–12.
13. Constantino F. et al Cluster-based spondyloarthritis phenotypes defined at baseline are predictive of 5-year severity outcome in the DESIR cohort. DOI: 10.1136/annrheumdis-2019-eular.3307.
14. Gao W. et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. // Ann Rheum Dis 2016; 75: 311–15.
15. Gossec L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update // Ann. Rheum. Dis. 2015; 0: 1–12.
16. Jadon DR et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype in psoriatic spondyloarthritis// Ann Rheum Dis 2017; 76: 701–707.
17. van der Heijde D et al. 2016 update of the ASAS-EU-LAR management recommendations for axial spondyloarthritis // Ann Rhem Dis 2017; 0: 1–14.
18. van der Heijde D et al. Tofacitinib in patients with ankylosing spondylitis: a phase2, 16-week, randomized, placebo-controlled, dose-ranging study/Ann Rheum Dis 2017; 76: 1340–7.
19. Kaaij MH et al. The link between angiogenesis and osteogenesis in spondyloarthritis/ DOI: 10.1136/annrheumdis-2018-eular.4419
20. McGonagle DG et al. The role of IL-17 in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies / Ann Rheum Dis 2019; 78: 1167–78.
21. Miceli-Richard C., Dougados M. Tracking JAKs in spondyloarthritis: rationale and expectations / Ann Rheum Dis. 2017 Vol. 76, No 8, p. 1325–1326.
22. Paramatra J. et al HLA-B27 positive versus HLA-B27 negative spondyloarthritis: different phenotypes but similar disease burden/ doi: 10.1136/annrheumdis-2013-eular.1586.
23. Rudwaliet M. et al. The assessment of Spondyloarthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general // Ann Rheum Dis. 2011; 70: 25–31.
24. Smolen JS et al. / Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendation by international task force // Ann. Rheum. Dis. 2018, 77: 3–11.
Review
For citations:
Babaeva A.R., Kalinina E.V., Zvonorenko M.S., Kostriukova I.V. Spondyloarthritis phenotypes: rationale of evaluation in context of personified medicine. Medical alphabet. 2019;2(37):16-21. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-37(412)-16-21
Views:
547
Email this article 